Amantadine


Adamantane-derived multi-target neurotherapeutic agent with weak NMDA receptor antagonism, sigma-1 receptor agonism, and indirect dopaminergic activity

A tricyclic adamantane amine originally developed as an influenza A antiviral, subsequently repositioned for Parkinson’s disease and levodopa-induced dyskinesia, distinguished by a polypharmacological profile spanning NMDA receptor antagonism, sigma-1 receptor agonism, dopaminergic facilitation, and nicotinic acetylcholine receptor modulation.

Abstract

Amantadine (1-adamantanamine) is a small-molecule adamantane derivative that has undergone three distinct phases of clinical development since its original synthesis in the 1960s: as the first synthetic antiviral agent active against influenza A virus through blockade of the M2 ion channel protein; as an antiparkinsonian agent discovered serendipitously in 1968 and subsequently approved for the treatment of drug-induced extrapyramidal reactions and as adjunctive therapy in Parkinson’s disease; and, most recently, as a delayed-release and extended-release formulation (Gocovri) approved by the United States Food and Drug Administration in 2017 for the treatment of levodopa-induced dyskinesia in Parkinson’s disease. The compound occupies a distinctive position in clinical neuropharmacology by virtue of a polypharmacological profile that engages multiple molecular targets at therapeutically relevant concentrations. At the sigma-1 receptor, amantadine acts as an agonist with a Ki of approximately 7.44 micromolar, a mechanism that has been linked to the modulation of dopaminergic neurotransmission including enhancement of tyrosine hydroxylase activity, facilitation of striatal dopamine release, and inhibition of dopamine reuptake. The compound also functions as a negative allosteric modulator of alpha-4-beta-2 and alpha-7 nicotinic acetylcholine receptors, with IC50 values in the low-micromolar range, and exerts additional effects on potassium channels, aromatic amino acid decarboxylase, and glial-cell-derived neurotrophic factor expression.

The clinical evidence base for amantadine now spans six decades and includes approved indications in Parkinson’s disease (both as monotherapy for mild symptoms and as adjunctive therapy for levodopa-induced dyskinesia), drug-induced extrapyramidal reactions, and influenza A prophylaxis and treatment (now largely obsolete owing to widespread viral resistance). Off-label applications with meaningful clinical support include acceleration of functional recovery in traumatic brain injury with disorders of consciousness, as demonstrated in the landmark Giacino et al. (2012) randomized placebo-controlled trial published in the New England Journal of Medicine; management of fatigue in multiple sclerosis; and reduction of chorea in Huntington disease. Pharmacokinetics are characterized by high oral bioavailability (86 to 90 percent), minimal hepatic metabolism with predominantly renal excretion of unchanged drug, a plasma elimination half-life of approximately 12 hours in subjects with normal renal function (extending to 7 to 10 days in severe renal impairment), and the absence of significant cytochrome P450 involvement. The adverse-event profile includes central nervous system effects (insomnia, dizziness, hallucinations, confusion), peripheral edema, the distinctive dermatological finding of livedo reticularis, and, at supratherapeutic doses or in overdose, QT prolongation and cardiac arrhythmias. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph